Jul 25, 2017
Samsung and Merck launch Remicade biosim at 35% discount After the first biosimilar of Johnson & Johnson’s big-selling immunology drug Remicade hit the market last year at a modest discount, another has come along with a much deeper pricing slash. Samsung and marketing partner Merck & Co. Monday launched the...
Read More...
Jul 18, 2017
Takeda scores blockbuster Velcade patent reprieve till 2022 In a major lift for Takeda and its aging multiple myeloma blockbuster Velcade, a U.S. appeals court overturned a ruling that invalidated a key patent, granting new exclusivity that should translate to significant sales over time. Takeda will have exclusive ...
Read More...
Jul 12, 2017
Obstetrician and gynaecologist Brenda Fitzgerald will direct the US Centers for Disease Control and Prevention (CDC), which was announced on 7th July. Dr. Brenda Fitzgerald has led the Georgia Department of Public Health since 2011, and has championed early-intervention programmes to improve maternal health and coun...
Read More...
Jun 29, 2017
Merck targeted in global ransomware attack Merck & Co. was among those affected by a massive ransomware attack Tuesday that infiltrated the computer systems of companies around the world as well as government ministries in Ukraine. Merck confirmed in Twitter posts Tuesday that it was hit in the cyberattack but d...
Read More...
May 29, 2017
Vitiligo is a common acquired, idiopathic depigmentation disorder which affects at least 1% to 2% of the population irrespective of sex, race, or age. The onset of this disease occurs between the ages of 10 and 30. In this condition, patients progressively lose their skin color, mostly in patches. The patches ...
Read More...
Mar 29, 2017
Nearly two-thirds of the mutations that drive cancers are caused by errors that occur when cells copy DNA. The findings, published in Science are the latest argument in a long-running debate over how much the environment or intrinsic factors contribute to cancer. They also suggest that many cancer mutations are not ...
Read More...
Mar 03, 2017
The development of antibiotics is vital to our survival, yet the rise of antimicrobial resistance is threatening to make them ineffective in the near future. A recent study estimates 200,000 babies die each year as a result of the over-use Of Antibiotics. Overall Antibiotic-resistant microorganisms play a ...
Read More...
Feb 16, 2017
Mead Johnson Acquired By Reckitt Benckiser for $16.6 Billion Mead Johnson Nutrition Company (MJN), the manufacturer of infant formula and nutritional supplements, has agreed to be acquired by Britain's Reckitt Benckiser Group plc in a deal that values the former's equity at $16.6 billion. Mead Johnson shareholders w...
Read More...
Feb 14, 2017
In letter to Allergan, SEC says it will scrutinize industry's use of non-GAAP accounting When the SEC criticized Valeant Pharmaceuticals over its use of non-GAAP reporting, it seemed like a regulator barking at a company known for pushing the limits. But now the agency has fired a warning shot across the bow of the ...
Read More...
Feb 07, 2017
FDA approves Bristol-Myers Squibb’s Opdivo injection to treat mUC Bristol-Myers Squibb’s Opdivo injection (nivolumab) has been approved by U.S. FDA for intravenous use in previously treated, locally advanced or metastatic urothelial carcinoma (mUC), a type of bladder cancer. This indication is approved based on tumo...
Read More...
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Newsletter/Whitepaper